CN119013281A - 作为apol1抑制剂的4'，5'-二氢螺[哌啶-4，7'-噻吩并[2，3-c]吡喃]衍生物和其使用方法 - Google Patents

作为apol1抑制剂的4'，5'-二氢螺[哌啶-4，7'-噻吩并[2，3-c]吡喃]衍生物和其使用方法 Download PDF

Info

Publication number
CN119013281A
CN119013281A CN202380032015.3A CN202380032015A CN119013281A CN 119013281 A CN119013281 A CN 119013281A CN 202380032015 A CN202380032015 A CN 202380032015A CN 119013281 A CN119013281 A CN 119013281A
Authority
CN
China
Prior art keywords
alkyl
group
optionally substituted
independently selected
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380032015.3A
Other languages
English (en)
Chinese (zh)
Inventor
T·J·森特
S·安格
M·A·布罗德尼
J·曹
J·科姆
L·A·达金
E·多尔基克
Z·加勒-戴
E·B·克吕格尔
S·南塔库马尔
J·H·奥尔森
A·J·希米祖
S·D·斯通
王皓轩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN119013281A publication Critical patent/CN119013281A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN202380032015.3A 2022-02-08 2023-02-08 作为apol1抑制剂的4'，5'-二氢螺[哌啶-4，7'-噻吩并[2，3-c]吡喃]衍生物和其使用方法 Pending CN119013281A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263307876P 2022-02-08 2022-02-08
US63/307876 2022-02-08
PCT/US2023/012578 WO2023154309A1 (en) 2022-02-08 2023-02-08 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same

Publications (1)

Publication Number Publication Date
CN119013281A true CN119013281A (zh) 2024-11-22

Family

ID=85685675

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380032015.3A Pending CN119013281A (zh) 2022-02-08 2023-02-08 作为apol1抑制剂的4'，5'-二氢螺[哌啶-4，7'-噻吩并[2，3-c]吡喃]衍生物和其使用方法

Country Status (7)

Country Link
US (1) US20250136612A1 (https=)
EP (1) EP4476228A1 (https=)
JP (1) JP2025505644A (https=)
CN (1) CN119013281A (https=)
AU (1) AU2023218939A1 (https=)
CA (1) CA3251124A1 (https=)
WO (1) WO2023154309A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI848031B (zh) 2018-12-17 2024-07-11 美商維泰克斯製藥公司 Apol1抑制劑及其使用方法
WO2021154997A1 (en) 2020-01-29 2021-08-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
CA3185604A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
WO2021252863A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and using the same
IL300298B2 (en) 2020-08-26 2025-06-01 Vertex Pharma Inhibitors of apol1 and methods of using same
IL314330A (en) 2022-01-18 2024-09-01 Maze Therapeutics Inc Apol1 inhibitors and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2020414A1 (en) * 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
WO2021220178A1 (en) * 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications
WO2021252849A1 (en) * 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same

Also Published As

Publication number Publication date
CA3251124A1 (en) 2023-08-17
US20250136612A1 (en) 2025-05-01
EP4476228A1 (en) 2024-12-18
AU2023218939A1 (en) 2024-08-22
JP2025505644A (ja) 2025-02-28
WO2023154309A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
CN119013281A (zh) 作为apol1抑制剂的4'，5'-二氢螺[哌啶-4，7'-噻吩并[2，3-c]吡喃]衍生物和其使用方法
US12421249B2 (en) Inhibitors of APOL1 and methods of using same
KR101624365B1 (ko) Ｃ형 간염 바이러스 억제제
CN108623615B (zh) 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用
CN102378762B (zh) 丙型肝炎病毒抑制剂
AU2012214767B2 (en) Hepatitis C virus inhibitors
EP4129996A1 (en) Novel aminopyrimidine egfr inhibitor
CN118632850A (zh) Apol1的螺环抑制剂和其使用方法
CN119343353A (zh) 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法
JP2018521005A (ja) ウレア誘導体、またはその薬理学的に許容される塩
TW201249834A (en) Hepatitis C virus inhibitors
CN119212986A (zh) 作为apol1的抑制剂的螺哌啶衍生物及其使用方法
IL301567A (en) A compound as an AKT KINASE inhibitor
WO2023077070A1 (en) Rxfp1 agonists
EA018331B1 (ru) Пирролопиримидинкарбоксамиды
JP7843780B2 (ja) 癌の処置に使用するための２，８－ジヒドロピラゾロ［３，４－ｂ］インドール誘導体
TWI915407B (zh) Ａｐｏｌ１抑制劑及其使用方法
OA21175A (en) Inhibitors of APOL1 and methods of using same.
SG187561A1 (en) 2,3,5-trisubstituted thiophene compounds and uses thereof
HK40030345B (en) Morpholinylpyridone compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination